# SELLAS Shares Rise More Than 200% After Leukemia Vaccine Meets Trial Goal

By Enna Lee

Canonical URL: https://www.tokenpost.com/news/investing/59510
Published: 2026-11-17T14:55:03.000Z
Updated: 2026-11-17T14:55:03.000Z
Section: Investing

> Median survival was 24.0 months for patients receiving galinpepimut-S, compared with 14.7 months for the comparison group.

Shares of SELLAS Life Sciences Group, Inc. (SLS) rose more than 200% Tuesday after its experimental leukemia vaccine met the main survival goal in a Phase 3 trial.

The REGAL trial tested galinpepimut-S, or GPS, in patients with acute myeloid leukemia. Participants were in a second or later complete remission and were ineligible for, or unable to undergo, a stem cell transplant. They received GPS alone as maintenance treatment or the comparison treatment.

Median overall survival was 24.0 months for patients receiving GPS, compared with 14.7 months for the comparison group. The trial found a 41% lower risk of death with GPS. The final analysis followed 80 events, the threshold set in the study plan.

SELLAS identified no new safety signals. Most treatment-related side effects were mild or moderate, with injection-site reactions the most common.

The findings are topline results for an experimental treatment in a specific group of leukemia patients. SELLAS plans to meet with the FDA to discuss the results and an accelerated filing strategy while preparing a biologics license application for the first half of 2027.


